Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
24. Oktober 2024 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
India Clinical Trials Market By Region, Competition, Forecast & Opportunities, 2020-2024 & 2024-2030
20. September 2024 04:59 ET
|
Research and Markets
Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "India Clinical Trials Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's...
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
06. Juni 2024 08:30 ET
|
Vaccinex, Inc.
Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.
Global Real World Evidence Solutions Market to 2028: Increased Emphasis on Comprehensive RWE Services Drives Growth
03. April 2023 04:33 ET
|
Research and Markets
Dublin, April 03, 2023 (GLOBE NEWSWIRE) -- The "Global Real World Evidence Solutions Market Size, Share & Industry Trends Analysis Report By Component, By Therapeutic Area, By End-user, By...
Physeon Positive Clinical Trial Results for its Veinplicity® Device to be Published in The Journal of Vascular Access
01. April 2019 09:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon’s Veinplicity Device Featured on ABC Affiliate KSTP Channel 5
14. Februar 2019 13:42 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Mayo Clinic to Conduct US “VIVA” Trial for Veinplicity
04. Februar 2019 08:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon Positive Clinical Trial Results for its Veinplicity® Device Published in The Journal of Vascular Access
21. Januar 2019 08:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon Bolsters Management Team with New Appointments
17. Dezember 2018 08:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced the...
Physeon Announces Enrollment of First Patient in US “VIVA” Trial for Veinplicity
12. November 2018 09:00 ET
|
Physeon
Important Milestone for Veinplicity Study SCHAFFHAUSEN, Switzerland, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology...